Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 5175-5177

  Butterfield, Jill M ^a   Lodise, Thomas P ^a   Beegle, Scott ^b   Rosen, Jonathan ^b   Farkas, Joshua ^b   Pai, Manjunath P ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOBRAMYCIN;

ACUTE PULMONARY EXACERBATION; ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL EVALUATION; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LUNG DISEASE; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NEPHROTOXICITY; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADULT; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSEUDOMONAS INFECTIONS; TOBRAMYCIN; YOUNG ADULT;

EID: 84884260746     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00539-13     Document Type: Article

References (24)

1. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. 2004. Cystic fibrosis adult care: consensus conference report. Chest 125:1S-39S.
2. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Kehagia V, Jones GR, Bruce KD. 2005. Bacterial activity in cystic fibrosis lung infections. Respir. Res. 6:49.
3. Lyczak JB, Cannon CL, Pier GB. 2002. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15:194-222.
4. Cystic Fibrosis Foundation. 2012. Patient registry 2011 annual data report. Cystic Fibrosis Foundation, Bethesda, MD.
5. SICOR Pharmaceuticals, Inc. 2005. June. Package literature for tobramycin. Sicor Pharmaceuticals, Inc., Irvine, CA.
6. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. 1984. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J. Pediatr. 105:117-124.
7. Bauer LA, Piecoro JJ, Jr, Wilson HD, Blouin RA. 1983. Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis. Clin. Pharm. 2:262-264.
8. Chuck SK, Raber SR, Rodvold KA, Areff D. 2000. National survey of extended-interval aminoglycoside dosing. Clin. Infect. Dis. 30:433-439.
9. Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T. 2006. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J. Antimicrob. Chemother. 58:822-829.
10. Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ. 2000. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob. Agents Chemother. 44:809-813.
11. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. 2012. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther. Drug Monit. 34:467-476.
12. Lodise TP, Jr, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. 2004. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob. Agents Chemother. 48:4718- 4724.
13. D'Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
14. Drusano GL, Louie A. 2011. Optimization of aminglycoside therapy. Antimicrob. Agents Chemother. 55:2528-2531.
15. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS, Jr. 1999. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gramnegative bacteria. Antimicrob. Agents Chemother. 43:623-629.
16. Mouton JW, Jacobs N, Tiddens H, Horrevorts AM. 2005. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn. Microbiol. Infect. Dis. 52:123-127.
17. Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. 2002. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur. Respir. J. 19:303-309.
18. Bates RD, Nahata MC, Jones JW, McCoy K, Young G, Cox S, Barson WJ. 1997. Pharmacokinetics and safety of tobramycin after once daily administration in patients with cystic fibrosis. Chest 112:1208-1213.
19. Martinez MN, Papich MG, Drusano GL. 2012. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/ pharmacodynamic target. Antimicrob. Agents Chemother. 56: 2795-2805.
20. Florescu MC, Lyden E, Murphy PJ, Florescu DF, Fillaus J. 2012. Long-term effect of chronic intravenous and inhaled nephrotoxic antibiotic treatment on the renal function of patients with cystic fibrosis. Hemodial. Int. 16:414-419.
21. Pedersen SS, Jensen T, Osterhammel D, Osterhammel P. 1987. Cummulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrob. Agents Chemother. 31:594-599.
22. Bertenshaw C, Watson AR, Lewis S, Smyth A. 2007. Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax 62:541-545.
23. Zamorano L, Juan C, Fernandez-Olmos A, Ge Y, Canton R, Oliver A. 2010. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin. Microbiol. Infect. 16:1482-1487.
24. Plummer A, Wildman M. 2013. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst. Rev. 5(1): CD006682. doi:10.1002/14651858.CD006682.pub4.